Literature DB >> 27246312

Imaging of Sleeping Beauty-Modified CD19-Specific T Cells Expressing HSV1-Thymidine Kinase by Positron Emission Tomography.

Amer M Najjar1, Pallavi R Manuri2, Simon Olivares1, Leo Flores3, Tiejuan Mi1, Helen Huls1, Elizabeth J Shpall4, Richard E Champlin4, Nashaat Turkman5, Vincenzo Paolillo6, Jason Roszik2, Brian Rabinovich1, Dean A Lee1,7, Mian Alauddin3, Juri Gelovani5, Laurence J N Cooper8,9.   

Abstract

PURPOSE: We have incorporated a positron emission tomography (PET) functionality in T cells expressing a CD19-specific chimeric antigen receptor (CAR) to non-invasively monitor the adoptively transferred cells. PROCEDURES: We engineered T cells to express CD19-specific CAR, firefly luciferase (ffLuc), and herpes simplex virus type-1 thymidine kinase (TK) using the non-viral-based Sleeping Beauty (SB) transposon/transposase system adapted for human application. Electroporated primary T cells were propagated on CD19+ artificial antigen-presenting cells.
RESULTS: After 4 weeks, 90 % of cultured cells exhibited specific killing of CD19+ targets in vitro, could be ablated by ganciclovir, and were detected in vivo by bioluminescent imaging and PET following injection of 2'-deoxy-2'-[18F]fluoro-5-ethyl-1-β-D-arabinofuranosyl-uracil ([18F]FEAU).
CONCLUSION: This is the first report demonstrating the use of SB transposition to generate T cells which may be detected using PET laying the foundation for imaging the distribution and trafficking of T cells in patients treated for B cell malignancies.

Entities:  

Keywords:  B cell malignancy; Chimeric antigen receptor; Immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27246312      PMCID: PMC5096958          DOI: 10.1007/s11307-016-0971-8

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  32 in total

1.  Simplified process for the production of anti-CD19-CAR-engineered T cells.

Authors:  Barbara Tumaini; Daniel W Lee; Tasha Lin; Luciano Castiello; David F Stroncek; Crystal Mackall; Alan Wayne; Marianna Sabatino
Journal:  Cytotherapy       Date:  2013-08-28       Impact factor: 5.414

2.  Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.

Authors:  Lisa Marie Serrano; Timothy Pfeiffer; Simon Olivares; Tontanai Numbenjapon; Jennifer Bennitt; Daniel Kim; David Smith; George McNamara; Zaid Al-Kadhimi; Joseph Rosenthal; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

3.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

Authors:  Claudia M Kowolik; Max S Topp; Sergio Gonzalez; Timothy Pfeiffer; Simon Olivares; Nancy Gonzalez; David D Smith; Stephen J Forman; Michael C Jensen; Laurence J N Cooper
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

4.  Preemptive control of graft-versus-host disease in a murine allogeneic transplant model using retrovirally transduced murine suicidal lymphocytes.

Authors:  S M Kornblau; I Stiouf; V Snell; D Przepiorka; L C Stephens; R Champlin; F C Marini
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

5.  Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects.

Authors:  Pritha Ray; Roger Tsien; Sanjiv Sam Gambhir
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

6.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

7.  piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies.

Authors:  Pallavi V Raja Manuri; Matthew H Wilson; Sourindra N Maiti; Tiejuan Mi; Harjeet Singh; Simon Olivares; Margaret J Dawson; Helen Huls; Dean A Lee; Pulivarthi H Rao; Joseph M Kaminski; Yozo Nakazawa; Stephen Gottschalk; Partow Kebriaei; Elizabeth J Shpall; Richard E Champlin; Laurence J N Cooper
Journal:  Hum Gene Ther       Date:  2010-04       Impact factor: 5.695

8.  PET imaging of T cells derived from umbilical cord blood.

Authors:  H Singh; A M Najjar; S Olivares; R Nishii; U Mukhopadhyay; M Alauddin; P R Manuri; H Huls; D A Lee; G Dotti; C Bollard; P J Simmons; E J Shpall; R E Champlin; J G Gelovani; L J N Cooper
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

9.  Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU.

Authors:  Gianpietro Dotti; Mei Tian; Barbara Savoldo; Amer Najjar; Laurence J N Cooper; James Jackson; Amanda Smith; Osama Mawlawi; Rajesh Uthamanthil; Agatha Borne; David Brammer; Vincenzo Paolillo; Mian Alauddin; Carlos Gonzalez; David Steiner; William K Decker; Frank Marini; Steven Kornblau; Catherine M Bollard; Elizabeth J Shpall; Juri G Gelovani
Journal:  Mol Imaging       Date:  2009 Jul-Aug       Impact factor: 4.488

10.  Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.

Authors:  Catherine M Bollard; Laura Aguilar; Karin C Straathof; Benedikt Gahn; M Helen Huls; Alexandra Rousseau; John Sixbey; M Victoria Gresik; George Carrum; Melissa Hudson; Dagmar Dilloo; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  J Exp Med       Date:  2004-12-20       Impact factor: 14.307

View more
  12 in total

Review 1.  Noninvasive PET Imaging of T cells.

Authors:  Weijun Wei; Dawei Jiang; Emily B Ehlerding; Quanyong Luo; Weibo Cai
Journal:  Trends Cancer       Date:  2018-04-17

2.  Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.

Authors:  Simone Krebs; Afruja Ahad; Lukas M Carter; Justin Eyquem; Christian Brand; Meghan Bell; Vladimir Ponomarev; Thomas Reiner; Claude F Meares; Stephen Gottschalk; Michel Sadelain; Steven M Larson; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2018-06-14       Impact factor: 10.057

Review 3.  Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors:  Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal:  Lancet Oncol       Date:  2017-10-31       Impact factor: 41.316

Review 4.  Application and Design of Switches Used in CAR.

Authors:  Paweł Głowacki; Piotr Rieske
Journal:  Cells       Date:  2022-06-13       Impact factor: 7.666

5.  Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy.

Authors:  Sarah M Larson; Laurel C Truscott; Tzu-Ting Chiou; Amie Patel; Roy Kao; Andy Tu; Tulika Tyagi; Xiang Lu; David Elashoff; Satiro N De Oliveira
Journal:  Hum Vaccin Immunother       Date:  2017-01-06       Impact factor: 4.526

6.  Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy.

Authors:  Victoria G Kravets; Yi Zhang; Hongxing Sun
Journal:  J Immunol Res Ther       Date:  2017-06-29

7.  T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.

Authors:  Kristine E Mayer; Sabine Mall; Nahid Yusufi; Dario Gosmann; Katja Steiger; Lisa Russelli; Henrique de Oliviera Bianchi; Stefan Audehm; Ricarda Wagner; Eva Bräunlein; Anja Stelzl; Florian Bassermann; Wilko Weichert; Wolfgang Weber; Markus Schwaiger; Calogero D'Alessandria; Angela M Krackhardt
Journal:  Theranostics       Date:  2018-11-28       Impact factor: 11.556

8.  Considerations when treating high-grade pediatric glioma patients with immunotherapy.

Authors:  Erin Crotty; Kira Downey; Lauren Ferrerosa; Catherine Flores; Bindu Hegde; Scott Raskin; Eugene Hwang; Nicholas Vitanza; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2020-12-17       Impact factor: 4.618

9.  Development of a Clinically Relevant Reporter for Chimeric Antigen Receptor T-cell Expansion, Trafficking, and Toxicity.

Authors:  Reona Sakemura; Aditya Bansal; Elizabeth L Siegler; Mehrdad Hefazi; Nan Yang; Roman H Khadka; Alysha N Newsom; Michael J Hansen; Michelle J Cox; Claudia Manriquez Roman; Kendall J Schick; Ismail Can; Erin E Tapper; Wendy K Nevala; Mohamad M Adada; Evandro D Bezerra; Lionel Aurelien Kankeu Fonkoua; Paulina Horvei; Michael W Ruff; Sameer A Parikh; Mukesh K Pandey; Timothy R DeGrado; Lukkana Suksanpaisan; Neil E Kay; Kah-Whye Peng; Stephen J Russell; Saad S Kenderian
Journal:  Cancer Immunol Res       Date:  2021-07-08       Impact factor: 12.020

Review 10.  Prospects for combined use of oncolytic viruses and CAR T-cells.

Authors:  Adam Ajina; John Maher
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.